NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
18/02/2025
Voltar para busca
Dado oficial do USPTO
PREDICTSCRIPT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
49
Atualização mais recente
18/02/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
25/10/2021
Data de registro
18/02/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/02/2025
Última transação
18/02/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2023-02-00
Primeiro uso no comércio
2023-02-00
Código do desenho
4
Tipo de titular
03
Localização do titular
Plymouth, MI
Examinador
MAHONEY, KATHERINE
Unidade examinadora
N90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Phenomics Health Inc.
Representantes
ROGER H. BORA THOMPSON HINE LLP
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Scientific and technological services in the field of pharmaceuticals featuring scientific testinganalysis and evaluation of blood samples for the purpose of drug development by othersdata-driven analytics and reporting to developers of drugs; scientific and technological services in the field of pharmaceuticals featuring scientific testinganalysis and evaluation of blood samples for the purpose of improving quality in the field of healthcare servicesspecifically for improving the monitoring and diagnostics of quantitative patient drug exposurethe monitoring and diagnostics of patient drug compliancedata-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activitiesdrug dosage recommendationsinitial drug prescribingdrug switchingall for research purposes and not for medical purposes; genetic testing for scientific research purposesspecifically pharmacogenomic testinganalysisevaluation of buccalsaliva and other biological samples for the purposes of analyzing how the genetic makeup of an individual affects their response to drugsimproving drug selection and dosage recommendationsselecting initial and subsequent medicationsidentifying drug-drug interactionsavoiding adverse drug reactionsdeveloping clinical treatment decision support recommendationssupporting other medical diagnostic products and prescription drugs; genetic testing for scientific research purposesanalysis of multiple genes and genetic variants and their effect on drug response across multiple therapeutic areasincluding but not limited to psychiatrypaincardiologyoncology; scientific and technological services in the field of pharmaceuticals in the nature of scientific testinganalysis and evaluation of biological samples for research purposesspecifically research in the field of clinical trialsresearch in the field of new drug development and drug repurposing
Publicações
Histórico de despachos e eventos da marca no USPTO.
49 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
18/02/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
27/01/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
27/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/01/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/01/2025
ALIE
ASSIGNED TO LIE
24/01/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/01/2025
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
13/01/2025
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
13/01/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
15/10/2024
GNRT
NON-FINAL ACTION E-MAILED
15/10/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
15/10/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
15/06/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
15/06/2024
IUAF
USE AMENDMENT FILED
13/05/2024
EISU
TEAS STATEMENT OF USE RECEIVED
13/05/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/05/2024
EX1G
SOU EXTENSION 1 GRANTED
10/05/2024
EXT1
SOU EXTENSION 1 FILED
10/05/2024
EEXT
SOU TEAS EXTENSION RECEIVED
10/05/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
14/11/2023
EXPT
EXPARTE APPEAL TERMINATED
20/10/2023
EXPT
EXPARTE APPEAL TERMINATED
19/10/2023
EXDM
EXPARTE APPEAL DISMISSED AS MOOT
19/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/09/2023
PUBO
PUBLISHED FOR OPPOSITION
19/09/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/08/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/08/2023
EXPI
EX PARTE APPEAL-INSTITUTED
08/08/2023
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
08/08/2023
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
08/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/08/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
03/08/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
27/04/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
27/04/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/02/2023
GNFR
FINAL REFUSAL E-MAILED
10/02/2023
CNFR
FINAL REFUSAL WRITTEN
10/02/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/01/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/01/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/07/2022
GNRT
NON-FINAL ACTION E-MAILED
05/07/2022
CNRT
NON-FINAL ACTION WRITTEN
05/07/2022
DOCK
ASSIGNED TO EXAMINER
15/06/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/11/2021
NWAP
NEW APPLICATION ENTERED
28/10/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PREDICTSCRIPT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.